Cargando…
Coronavirus disease 2019 (COVID-19): current status and future perspectives
Coronavirus disease 2019 (COVID-19) originated in the city of Wuhan, Hubei Province, Central China, and has spread quickly to 72 countries to date. COVID-19 is caused by a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [previously provisionally known as 2019 no...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V. and International Society of Chemotherapy.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139247/ https://www.ncbi.nlm.nih.gov/pubmed/32234466 http://dx.doi.org/10.1016/j.ijantimicag.2020.105951 |
_version_ | 1783518722614362112 |
---|---|
author | Li, Heng Liu, Shang-Ming Yu, Xiao-Hua Tang, Shi-Lin Tang, Chao-Ke |
author_facet | Li, Heng Liu, Shang-Ming Yu, Xiao-Hua Tang, Shi-Lin Tang, Chao-Ke |
author_sort | Li, Heng |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19) originated in the city of Wuhan, Hubei Province, Central China, and has spread quickly to 72 countries to date. COVID-19 is caused by a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [previously provisionally known as 2019 novel coronavirus (2019-nCoV)]. At present, the newly identified SARS-CoV-2 has caused a large number of deaths with tens of thousands of confirmed cases worldwide, posing a serious threat to public health. However, there are no clinically approved vaccines or specific therapeutic drugs available for COVID-19. Intensive research on the newly emerged SARS-CoV-2 is urgently needed to elucidate the pathogenic mechanisms and epidemiological characteristics and to identify potential drug targets, which will contribute to the development of effective prevention and treatment strategies. Hence, this review will focus on recent progress regarding the structure of SARS-CoV-2 and the characteristics of COVID-19, such as the aetiology, pathogenesis and epidemiological characteristics. |
format | Online Article Text |
id | pubmed-7139247 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier B.V. and International Society of Chemotherapy. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71392472020-04-08 Coronavirus disease 2019 (COVID-19): current status and future perspectives Li, Heng Liu, Shang-Ming Yu, Xiao-Hua Tang, Shi-Lin Tang, Chao-Ke Int J Antimicrob Agents Article Coronavirus disease 2019 (COVID-19) originated in the city of Wuhan, Hubei Province, Central China, and has spread quickly to 72 countries to date. COVID-19 is caused by a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [previously provisionally known as 2019 novel coronavirus (2019-nCoV)]. At present, the newly identified SARS-CoV-2 has caused a large number of deaths with tens of thousands of confirmed cases worldwide, posing a serious threat to public health. However, there are no clinically approved vaccines or specific therapeutic drugs available for COVID-19. Intensive research on the newly emerged SARS-CoV-2 is urgently needed to elucidate the pathogenic mechanisms and epidemiological characteristics and to identify potential drug targets, which will contribute to the development of effective prevention and treatment strategies. Hence, this review will focus on recent progress regarding the structure of SARS-CoV-2 and the characteristics of COVID-19, such as the aetiology, pathogenesis and epidemiological characteristics. Elsevier B.V. and International Society of Chemotherapy. 2020-05 2020-03-29 /pmc/articles/PMC7139247/ /pubmed/32234466 http://dx.doi.org/10.1016/j.ijantimicag.2020.105951 Text en © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Li, Heng Liu, Shang-Ming Yu, Xiao-Hua Tang, Shi-Lin Tang, Chao-Ke Coronavirus disease 2019 (COVID-19): current status and future perspectives |
title | Coronavirus disease 2019 (COVID-19): current status and future perspectives |
title_full | Coronavirus disease 2019 (COVID-19): current status and future perspectives |
title_fullStr | Coronavirus disease 2019 (COVID-19): current status and future perspectives |
title_full_unstemmed | Coronavirus disease 2019 (COVID-19): current status and future perspectives |
title_short | Coronavirus disease 2019 (COVID-19): current status and future perspectives |
title_sort | coronavirus disease 2019 (covid-19): current status and future perspectives |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139247/ https://www.ncbi.nlm.nih.gov/pubmed/32234466 http://dx.doi.org/10.1016/j.ijantimicag.2020.105951 |
work_keys_str_mv | AT liheng coronavirusdisease2019covid19currentstatusandfutureperspectives AT liushangming coronavirusdisease2019covid19currentstatusandfutureperspectives AT yuxiaohua coronavirusdisease2019covid19currentstatusandfutureperspectives AT tangshilin coronavirusdisease2019covid19currentstatusandfutureperspectives AT tangchaoke coronavirusdisease2019covid19currentstatusandfutureperspectives |